in a previous threemonth study of meriva a proprietary curcuminphosphatidylcholine phytosome complex decreased joint pain and improvement in joint function were observed in 50 osteoarthritis oa patientssince oa is a chronic condition requiring prolonged treatment the longterm efficacy and safety of meriva were investigated in a longer eight months study involving 100 oa patientsthe clinical end points western ontario and mcmaster universities womac score karnofsky performance scale index and treadmill walking performance were complemented by the evaluation of a series of inflammatory markers interleukin il1beta il6 soluble cd40 ligand scd40l soluble vascular cell adhesion molecule svcam1 and erythrocyte sedimentation rate esrthis represents the most ambitious attempt to date to evaluate the clinical efficacy and safety of curcumin as an antiinflammatory agentsignificant improvements of both the clinical and biochemical end points were observed for meriva compared to the control groupthis coupled with an excellent tolerability suggests that meriva is worth considering for the longterm complementary management of osteoarthritis